Children in the world's poorest countries to get free insulin

Novo NordiskNovo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo.

It is estimated that some 38,000 African children aged 0–14 have type 1 diabetes. Sick children are particularly vulnerable in poor countries. A child in sub-Saharan Africa diagnosed with type 1 diabetes has a life expectancy of less than one year. A child with the same condition in the developed world has the possibility to live a full life.

"The premature death of a child caused by lack of insulin is unacceptable, when a life-saving solution is available. We must work together across borders to keep these children from dying; this is why I welcome this new programme being launched by Novo Nordisk today," says Professor Jean Claude Mbanya, president-elect of the International Diabetes Federation (IDF).

The programme will be based on a hub-and-spoke concept (satellite centres around existing hospitals/clinics) aimed at building long-term solutions for improving availability, accessibility, affordability and quality of diabetes care for children with type 1 diabetes.

"As a diabetes care company we have an obligation to use our resources and expertise to help these children. This project will not only provide insulin free of charge to an extremely vulnerable group, it is also designed to build long-term solutions for insulin distribution and sustainable diabetes care for all people with diabetes in the world's poorest countries," says Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk A/S.

To this end, the project’s aim is to collaborate with as many local partners as possible, including governments and diabetes associations, regional chapters of the International Diabetes Federation (IDF) and key opinion leaders. Efforts to improve the healthcare infrastructure of participating countries will also help the programme to survive after the project period ends.

"The World Diabetes Foundation is committed to funding capacity building, awareness creation and development of sustainable infrastructure within existing structures to improve the care for children with diabetes in developing countries. We will work with Novo Nordisk and other relevant stakeholders to achieve this objective," says Anil Kapur, managing director for the World Diabetes Foundation (WDF).

Novo Nordisk announced the 'Changing the Future for Children with Diabetes' programme in connection with the 60th anniversary of the United Nations Universal Declaration of Human Rights.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...